Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of “Buy” from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has received an average rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $20.83.

Several brokerages recently commented on ALT. Stifel Nicolaus initiated coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Wednesday. Finally, UBS Group began coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ALT. Sequoia Financial Advisors LLC boosted its holdings in Altimmune by 34.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 13,655 shares of the company’s stock worth $98,000 after purchasing an additional 3,500 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Altimmune in the 4th quarter worth $88,000. Cullen Frost Bankers Inc. purchased a new position in shares of Altimmune in the 4th quarter worth $72,000. Steward Partners Investment Advisory LLC increased its position in Altimmune by 38.9% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 28,050 shares of the company’s stock valued at $202,000 after acquiring an additional 7,850 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in Altimmune during the fourth quarter valued at $45,000. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Stock Down 3.6 %

Shares of ALT opened at $6.66 on Friday. The stock has a market cap of $473.69 million, a P/E ratio of -4.30 and a beta of 0.19. The business’s 50 day moving average price is $7.59 and its 200-day moving average price is $7.17. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84.

Altimmune (NASDAQ:ALT) last released its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter. During the same period last year, the firm posted ($0.39) earnings per share. On average, equities analysts anticipate that Altimmune will post -1.35 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.